EXPERIENCE WITH THE DRUG MEMANTINE IN PATIENTS WITH FOCAL EPILEPSY AND COGNITIVE IMPAIRMENT

Abstract

Abstract: cognitive impairment of varying degrees of severity identified in patients with focal epilepsy in 40-50% of cases. The incidence and severity of cognitive impairment depends on the cause epileptic seizures, localization of the lesion, antiepileptic therapy, and other factors. It should be noted that the correction capability of cognitive disorders in patients with epilepsy are somewhat limited because number of drugs used for the treatment are in the instructions for use as contraindications and indications of use ostoozhnostyu in patients with epilepsy. This work reflects the results of a prospective uncontrolled focal observations efficiency NMDA-receptor antagonist: This drug memantine (Noodzheron). The study involved 50 patients with focal epilepsy and having symptoms of cognitive deficits of varying severity. Evaluating the effectiveness carried out in 2 months from the start of the reception, the dosage of 5.10 mg × 1 time per day. After the treatment, a statistically significant improvement in cognitive function based on the results of tests: Mini-mental state examination, clock drawing test, the test Luria test “symbols and numbers.” Noodzheron taking the drug had no effect on the frequency of epileptic seizures.